Tuvatexib

Vidac Pharma to present recent clinical and strategic progress at the 19th European Life Sciences CEO Forum by Sachs Associates. Conferences such as Sachs provide an important platform to share developments in our clinical programs and strategic initiatives.” — Dr. Max Herzberg LONDON, UNITED KINGDOM, February 16, 2026 / EINPresswire.com / -- Vidac Pharma Holdings Plc. announces that Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, will present at the 19th Annual European Life Sciences CEO Forum, organized by Sachs Associates, taking place on March 4–5, 2026, at the Hilton Zurich Airport Hotel. Dr. Herzberg will deliver a 20-minute presentation, including a Q&A session, on March 4, 2026, at 14:40 (Track C, Room Berne). During the presentation, he will provide an update on the Company’s recent progress, including clinical advancements, strategic developments, and the continued expansion of Vidac’s oncology pipeline. The European Life Sciences CEO Forum, hosted annually by Sachs Associates, is an international healthcare and life sciences investor conference that brings together senior executives from biotechnology and pharmaceutical companies with global institutional investors and strategic partners. Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, stated: “We look forward to presenting Vidac’s recent progress at the European Life Sciences CEO Forum and to engaging with the international investment and healthcare community. Conferences such as Sachs provide an important platform to share developments in our clinical programs and strategic initiatives.” Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations, assumptions, and information available to the Company at the time of publication and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, developments in research and development activities, clinical trial outcomes, regulatory requirements, intellectual property matters, financing needs, and market conditions. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law. About Vidac Pharma Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and mislocalization of the Hexokinase-2 metabolic checkpoint (HK2) in cancer cells to renormalize the tumor microenvironment and selectively provoke programmed cell death without affecting surrounding normal tissue. Vidac’s lead drug candidate, VDA-1102, has demonstrated efficacy against advanced Actinic Keratosis (AK) in Phase 2b studies. Positive results in Cutaneous T-cell Lymphoma (CTCL) in a Phase 2A trial. Max Herzberg Vidac pharma Holding Plc email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Vidac pharma Holding Plc (Xtra:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) This patent issuance represents an important milestone for Vidac Pharma. It strengthens the protection of our novel small chemical entities targeting HK2–mitochondrial interactions” — Dr. Max Herzberg LONDON, UNITED KINGDOM, January 12, 2026 / EINPresswire.com / -- Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for one of its core patents. The granted patent provides protection for a broad range of applications related to the development of molecules that modulate the interaction of hexokinase 2 (HK2) with mitochondria. The Notice of Issuance was received on January 8 2026. The patent will be published as granted on January 20 by the USPTO. In addition, the Company has filed continuation-in-part applications based on the same fundamental mechanism identified by its research group, with the objective of further developing and expanding its intellectual property portfolio. Dr. Max Herzberg, Chairman and Chief Executive Officer of Vidac Pharma, stated: “This patent issuance represents an important milestone for Vidac Pharma. It strengthens the protection of our novel small chemical entities targeting HK2–mitochondrial interactions. Depending on jurisdiction, the patent provides protection for up to 20 years from the filing date, with the possibility of extensions where applicable. An increasing body of scientific literature highlights the role of mitochondrial function in cellular metabolism, including in the field of oncology.” Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are based on current expectations, assumptions, and information available to the Company at the time of publication and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, developments in research and development activities, regulatory requirements, intellectual property proceedings, and market conditions. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law. About Vidac Pharma Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and mislocalization of the Hexokinase-2 metabolic checkpoint (HK2) in cancer cells to renormalize the tumor microenvironment and selectively provoke programmed cell death without affecting surrounding normal tissue. VDA-1102, Vidac Pharma’s first drug candidate, has demonstrated effectiveness against advanced actinic keratosis (AK), while interim Phase 2 results in cutaneous T-cell lymphoma (CTCL) have shown promising clinical benefit in humans. Important Information The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holdings Plc but is for informational purposes only. This announcement contains forward-looking statements, including statements regarding the Company’s strategy, plans, and future prospects. Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law. Max Herzberg Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.